Drug intelligence / Profile preview

Tavoniza

Development stage: Approved
Lead developer: Atco Pharma
Modality: Small Molecules
Administration: Oral

Overview

Tavoniza is a brand name for vonoprazan, a potassium-competitive acid blocker (P-CAB) developed and marketed by Atco Pharma in Egypt. Launched in June 2023, it is used for the treatment of acid-related gastrointestinal disorders, including gastroesophageal reflux disease (GERD), gastric and duodenal ulcers, and as part of a regimen for Helicobacter pylori eradication. Unlike traditional proton pump inhibitors (PPIs), vonoprazan inhibits the H+/K+-ATPase enzyme in a reversible and potassium-competitive manner, providing a more rapid and sustained suppression of gastric acid secretion. Although listed under cardiovascular products in some company portfolios, it is primarily a gastrointestinal medication.

Brand names: Tavoniza
Other names: vonoprazan

Targets

ATP4A (Potassium–transporting ATPase alpha chain 1)

Beyond the preview

Go deeper on Tavoniza.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tavoniza.

Explore the full profile